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Aim: Gadolinium-based nanoparticles were functionalized with either the Pittsburgh 
compound B or a nanobody (B10AP) in order to create multimodal tools for an early 
diagnosis of amyloidoses. Materials & methods: The ability of the functionalized 
nanoparticles to target amyloid fibrils made of β-amyloid peptide, amylin or Val30Met-
mutated transthyretin formed in vitro or from pathological tissues was investigated by 
a range of spectroscopic and biophysics techniques including fluorescence microscopy. 
Results: Nanoparticles functionalized by both probes efficiently interacted with the 
three types of amyloid fibrils, with KD values in 10 micromolar and 10 nanomolar 
range for, respectively, Pittsburgh compound B and B10AP nanoparticles. Moreover, 
they allowed the detection of amyloid deposits on pathological tissues. Conclusion: 
Such functionalized nanoparticles could represent promising flexible and multimodal 
imaging tools for the early diagnostic of amyloid diseases, in other words, Alzheimer’s 
disease, Type 2 diabetes mellitus and the familial amyloidotic polyneuropathy.
First draft submitted: 10 March 2017; Accepted for publication: 24 May 2017; Published 
online: 21 June 2017
Keywords:  amyloid imaging • amyloidoses • gadolinium-based nanoparticles • nanobody 
• PIB
Amyloidoses are a set of human diseases in 
which a normally soluble peptide or protein 
aggregates into insoluble and highly orga-
nized aggregates referred to as amyloid fibres. 
These aggregates are rich in cross-β-sheet 
structures [1,2]. So far, 36 proteins are associ-
ated with either local (e.g., Type 2 diabetes 
mellitus [T2DM] and Alzheimer’s disease 
[AD]) or systemic (e.g., familial polyneurop-
athy and myeloma) amyloid depositions [3]. 
These diseases inflict enormous psycho-
sociological and economic burdens. For 
example, AD and T2DM affect, respectively, 
approximately 44 and 415 million people 
 worldwide [4,5].
Symptoms of amyloidoses, especially in 
the cases of systemic amyloidoses, can be 
very subtle and vary widely from person to 
person and also depend on which organs 
are affected. The diagnosis of amyloidosis 
and especially the early diagnosis, remains 
therefore a great challenge and often requires 
 several invasive examinations [6,7].
Therefore, there is a need to develop sen-
sitive and minimally invasive tools to detect 
amyloid deposits, in order not only to estab-
lish the diagnosis of amyloidosis [8] but also 
allow to follow-up the efficiency of treatment 
by monitoring the evolution of the amyloid 
load [9]. Nowadays, a number of imaging 
techniques can be used for these purposes; 
they include PET and MRI to detect the 
deposition of Aβ amyloid in the brain of AD 
patients [10,11], scintigraphy to detect V30M-
TTR fibrils involved in cardiac amyloido-
sis [12], autoradiography to target islet amyloid 
polypeptide (IAPP) fibrils in T2DM [13], etc. 
However, each of these techniques presents 
some limitations. For example, while MRI 
allows obtaining an outstanding spatial reso-
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lution it strongly lacks sensitivity (1–0.01 millimolar 
range) [14]. On the other hand, PET offers an excellent 
sensitivity (10–1 pM range) but has a low spatial reso-
lution [15]. In order to overcome these limitations, the 
development of probes allowing multimodal imaging 
approaches (i.e., combination of PET and MRI) will 
represent a breakthrough in the diagnosis of amyloido-
ses [16,17]. In this context, nanoparticles have emerged 
in the past decades as a very promising tool to enhance 
the contrast and the sensitivity of these different imag-
ing techniques.
In this work, we have functionalized gadolinium 
(Gd) based multimodal nanoparticles (NPs), so called 
AGuIX with specific probes for the diagnosis of amy-
loidoses. AGuIX are made of a polysiloxane network 
surrounded by several DOTAGA (Gd3+) chelates [18,19]. 
AGuIX NPs have a diameter smaller than 5 nm and 
have been already efficiently used for MRI and radio-
sensitization [20]. Free ligands are available at the sur-
face of AGuIX and can be used to chelate radioisotopes 
(e.g., 68Ga3+ or 111In3+), in order to perform PET or 
single-photon emission computed tomography imag-
ing [14,21]. Moreover, the covalent grafting of a near 
infrared dye, such as cyanine5.5 (Cy5.5), is also achiev-
able for optical imaging [22]. Finally, we have recently 
shown that AGuIX can be functionalized with specific 
Aβ peptides to selectively target and image Aβ-amyloid 
fibrils [23]. However, while the results obtained clearly 
demonstrate that these functionalized NPs constitute 
a valuable multimodal imaging tool to selectively tar-
get Aβ fibrils, they displayed a low affinity (100 μM 
range) for their target. Therefore, the aim of the present 
work is to functionalize AGuIX with molecules having 
higher affinity for amyloid fibrils, in order to develop a 
sensitive tool for early diagnosis of amyloidoses.
Among the molecules binding to amyloid fibrils 
with relatively high affinity, thioflavin (ThS or ThT) is 
probably the most used probe for the detection of amy-
loid aggregates, both in vitro for biochemical charac-
terization and ex vivo for histological studies [24]. Sev-
eral thioflavin-derived molecules have been designed to 
further increase its affinity for amyloid fibrils in order 
to enable PET applications [11]. One of these molecules, 
the Pittsburgh compound B (PIB), shows an affinity in 
the nanomolar range toward β-amyloid deposits [11,25–
26] and successfully targets senile plaques in Alzheim-
er’s patient [27]. This compound can be coupled to 
metal ion such as Gd3+ for MRI or to radioisotopes 
such as 111In3+ for single-photon emission computed 
tomography [28] or 11C or 18F for PET. As consequence, 
PIB is considered as the clinical ‘gold standard’ probe 
for amyloidoses including AD.
Another approach to image amyloid fibrils consists 
of functionalizing NPs with antibodies or antibody 
fragments displaying a high specificity and affinity 
for the targeted fibrils [29]. For example, an enhanced 
amyloid-β plaques detection by MRI was observed 
within AD transgenic mouse using SuperParamagnetic 
Iron Oxide Nanoparticles functionalized with an anti-
AβPP antibody [30]. In this work, we have chosen to 
functionalize AGuIX with the B10AP which is a chi-
meric protein made of B10, a nanobody (i.e., the vari-
able domain of heavy-chain antibodies) and Escherichia 
coli alkaline phosphatase (AP). B10 has been selected 
by phage display from a synthetic library of nanobod-
ies using Aβ
(1–40)
 fibrils as bait [31]. It also recognizes 
amyloid fibrils of several proteins (made in vitro and on 
tissues) including insulin, glucagon, β2-microglobulin, 
serum amyloid A protein and immunoglobulin light 
chain (AL) [32]. AP forms homodimers and therefore 
B10AP exhibits two copies of B10 within one molecule 
of the chimera; such a bivalent construct exhibits a 
higher overall affinity for Aβ
(1–42)
 amyloid fibrils with 
a lower dissociation constant (K
D
: 7 nM and 475 nM 
for B10AP and B10, respectively) [32]. Moreover, the 
phosphatase activity of AP allows an easy and straight-
forward monitoring of B10AP binding to the amyloid 
fibrils.
In this work, we have used PIB and B10AP as graft-
ing ligands on AGuIX NPs, in order to perform active 
targeting on Aβ
(1–42)
 fibrils which deposit in the brain 
of AD patients; IAPP fibrils that accumulate in Lang-
erhans Islet of patients affected with T2DM; and 




AGuIX were synthesized as previously described [18,19] 
(Nano-H SAS, Saint-Quentin Fallavier, France). These 
NPs are composed of a polysiloxane network sur-
rounded by covalently grafted DOTAGA (1,4,7,10-tet-
raazacyclododecane-1-glutaric anhydride-4,7,10-triace-
tic acid, CheMatech, Dijon, France) and Gd3+ chelates, 
with 5 or 7% free DOTA. NPs concentrations are 
stated in mol.L-1 of Gd element.
Functionalization of AGuIX NP with PIB NP
PIB derivative was synthesized as previously 
described [33]. In order to functionalize AGuIX with 
PIB, a polyethylene glycol bis-carboxymethyl (PEG) 
was first grafted on NP as previously described [23]; 
after purification, the AGuIX@PEG were freeze-
dried. Then, these freeze-dried NPs were dispersed at 
a Gd3+ concentration of 500 mM in ultrapure water 
and diluted tenfold with diethylene glycol (SDS Carlo 
Erba, France) at 80°C and then diluted twice with dry 
dimethyl sulfoxide (DMSO), leading to a final 25 mM 
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Gd3+. The carboxylic functions of the NPs were acti-
vated by N-(3-Dimethylaminopropyl)-N0-ethylcar-
bodiimidehydrochloride (EDC) and pentafluorophe-
nol (PFP) at EDC/PFP/Gd3+ molar ratio 10/20/1 for 
15 min. PIB at 200 mg.ml-1 in dry DMSO was added 
to the NPs suspension and the mixture was stirred 
for 6 h (PIB/Gd3+ molar ratio 1/1). Finally, the NPs 
were precipitated in acetone (Sodipro, France), centri-
fuged and the supernatant was removed; this step was 
repeated three-times to allow the removal of the upmost 
ungrafted PIB. After redispersion of the precipitate in 
water, acetone was evaporated overnight at 40°C in 
open vials. The unreacted reagents and the degraded 
NPs were efficiently eliminated by repeated concentra-
tion/dilution using tangential filtration cycles with a 
5 kDa molecular cut-off membrane. A full experimen-
tal characterization of the AGuIX@PEG@PIB samples 
is described in the Supplementary Information.
Functionalization of AGuIX NP with B10APB10AP 
was produced in E. coli and purified as described previ-
ously [31], from the plasmid ptetB10pA6H kindly pro-
vided by Prof Horn, Jena University, Germany. Freeze-
dried AGuIX with 7% of free DOTA (AGuIX@
DOTA
free7%
) were first labeled with one Cy5.5 dye mol-
ecule for 1000 Gd3+ as previously described [23], and 
then were dispersed at 100 mM in Gd3+ in ultrapure 
water. The carboxylic acid functions of the free DOTA 
ligand were activated using a 100-fold excess of EDC 
and N-hydroxysuccinimide. After 15 min of incuba-
tion, at room temperature under mild agitation, the 
activated AGuIX NPs were added in large excess (100-
fold excess) to the nanobody suspension at 41 μM in 
phosphate-buffered saline buffer. Ungrafted AGuIX 
were also added to the suspension in order to reach 
a Gd3+ concentration of 10 mM to stabilize grafted 
NPs. After 30 min of incubation, the ungrafted NPs 
are removed by tangential filtration on a 50kDa cut-off 
membrane. Then, the AGuIX@B10AP@Cy5.5 were 
freeze-dried and stored away from light. A full experi-
mental characterization of the AGuIX@B10AP@Cy5.5 
samples is described in the Supplementary Information.
EDC, PFP, PEG, N-hydroxysuccinimide (NHS) 





 fibrils were prepared from Aβ
(1–42)
 peptide 
(Genecust, Luxembourg), incubated at 100 μM, and 
the V30M-TTR fibrils from recombinant protein pro-
duced in E. coli and were prepared at 32.3 μM, as pre-
viously described [23].
IAPP fibrils (48 μM) were prepared using lyophi-
lized IAPP peptide (Genecust) dissolved in 100% 
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) and then 
incubated in Tris-HCl 20 mM pH 7.4 at 37°C for 
5 days, based on previous studies [34]. A full experi-
mental detail of IAPP fibrils is described in the 
 supplementary information.
The fibrillar morphology of the aggregates formed 
by the three peptides or proteins was confirmed 
using Transmission Electronic Microscopy analysis 
( JEOL1200EX/Tecnai 12).
In vitro assays & equilibrium constant 
determination
Dissociation constants (i.e., affinities) were obtained 
by partition binding tests between fibrils and func-
tionalized NPs as previously described [23]. Each 
type of fibrils, were incubated at 20 or 40 μM, with 
the following ranges of concentrations for AGuIX@
PEG@PIB, between 0.01 and 4 μM in PIB, and for 
AGuIX@B10AP@Cy5.5 between 0.16 and 132 nM in 
B10. According to the fluorescence properties of PIB 
(λ
ex
 = 350 nm, λ
em
 = 420 nm) or Cy5.5 (λ
ex
 = 655 nm, 
λ
em
 = 685 nm), fluorescence emission spectrum of each 
sample was recorded on a JASCO J-815 spectrophoto-
meter. Michaelis binding model was used to calculate 
the equilibrium constant affinity (K
D
) following the 
equation:
y Ym K xD= +/( ( / )),1
where (Ym) is the fluorescence intensity maximum 
and (y) is the fluorescence intensity measured for 
a given concentration in targeting probes within 
 functionalized NPs (x).
Animal models
Brain sections prepared from 18 months APPswe/
PSEN1dE9 AD mouse models (kindly provided by M 
Dhenain, Fontenay aux Roses, France) were used to 
target Aβ-peptide fibrils. These models were previously 
described in the literature [35,36], and a short description 
is provided within Supplementary Information. Brain 
sections from C57/Bl6 mice were used as control.
Pancreas sections were prepared from male mice 
homozygous for RIPHAT transgene-expressing 
human-IAPP as TDM2 models [37]. Pancreas from S/
FVB/NJ mice were used as control tissue without amy-
loid burden.
Stomach tissue sections were extracted from a trans-
genic mice expressing human V30M-TTR and lack-
ing endogenous mouse TTR [38]. Similar tissue from 
knockdown mice for transthyretin gene was used as 
control [39].
All the procedures involving animals were carried 
out in accordance with the European Community 
Council Directives. The different procedures to deeply 
anesthetize the animals, to extract and fix the organs/
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tissues and to prepare the sections are described in 
details within Supplementary Information. Tissue sec-
tions were mounted on slides for the immunostaining 
experiments.
Immunohistochemistry
Frozen sections were processed for immunohistochem-
istry staining with AGuIX@PEG@PIB and AGuIX@
B10AP@Cy5.5 as previously described with other func-
tionalized AGuIX [23]. AGuIX@PEG@PIB were used 
at (PIB) = 5 μM and AGuIX@B10AP@cy5.5 at (B10) 
= 81 nM. To each suspension of grafted NPs, 3 mM 
of ungrafted NPs were added to insure the stability of 
the former. In the case of PIB, fluorescence was used 
to monitor the binding of AGuIX@PEG@PIB (λ
ex
 = 
350 nm - λ
em
 = 405 nm). TRITC-conjugated phal-
loidin (Sigma, France, #P1951) was used to detect the 
actin network (λ
ex
 = 545 nm-λ
em
 = 605 nm). Regarding 
AGuIX@PEG@B10AP@Cy5.5, the binding to NPs to 
amyloid plaques was detected through either the fluo-
rescence of Cy5.5 (λ
ex
 = 650 nm-λ
em
 = 670 nm) or via 
the enzymatic activity of AP fused to B10AP using red 
permanent as substrate (λ
ex
 = 595 nm-λ
em
 = 613 nm). 
In all tissue sections, amyloid burden was stained with 
ThS (λ
ex
 = 450 nm - λ
em
 = 488 nm) (Sigma, #T1892) 
according to standard practice. Fluorescent images 
were recorded using either Zeiss confocal LSM800 
microscope for pancreas sections or Zeiss microscope 
Axiovert 200 M for brain and stomach tissues. Images 
were analyzed using Carl Zeiss AxioVision software 
and Image J 1.50f software.
Results
Characterization of the grafted NPs
The synthesis of functionalized AGuIX NPs was 
achieved through a bottom-up process described previ-
ously [18,19], with around ten DOTAGA per NP. Two 
different strategies were used to graft PIB and B10AP, 
mainly due to their sizes (Figure 1A). The addition of 
small PEG chains at the surface of AGuIX was nec-
essary to guarantee the accessibility of PIB (i.e., to 
limit the steric hindrance due to the proximity of the 
NP) for the interaction with amyloid aggregates. The 
hydrodynamic diameter (D
H
) of AGuIX increased 
from 2.9 ± 0.7 nm to 4.3 ± 1.0 nm after addition of 
PEG chains and to 6.5 ± 1.5 nm after PIB grafting 
(Figure 1B, Table 1). In addition, the relaxometric char-
acterization r
1
 slightly increased from naked AGuIX 
to AGuIX@PEG@PIB (Supplementary Table 1), from 
10 mM-1s-1 to 12.9 mM-1s-1. The number of molecules 
of PIB grafted on NPs was estimated by absorption 
spectroscopy (Figure 1C). A standard curve, in other 
words, absorbance at 338 nm (A
338
) as a function of 
(PIB), was first established with known solutions of 
PEG@PIB. The optical properties of PIB are sensitive 
to the solvent polarity, thus the standard curve was 
established taking into account [40,41]. Then, the PIB 
concentrations were estimated for two dilutions of the 
AGuIX@PEG@PIB stock solution (known [Gd3+]) to 
get the ratio between PIB and Gd3+. Then, the PIB 
concentrations were estimated for two dilutions of 
the AGuIX@PEG@PIB stock solution to get the ratio 
between PIB and Gd3+: it was evaluated to one PIB for 
50 Gd3+.
The strategy to graft B10AP was to use NPs display-
ing about 7% of free DOTA. B10AP was then directly 
bound to free carboxylic acid functions of these DOTA 
(Figure 1A). To allow their detection by fluorescence 
microscopy, Cy5.5 was grafted on the NPs before graft-
ing B10AP. The hydrodynamic diameter for AGuIX@
DOTA
7%free
, B10AP and AGuIX@B10AP@Cy5.5 is 
4.2 ± 0.7 nm, 9.2 ± 2.9 nm and 13.9 ± 2.6 nm, respec-
tively (Figure 1D). The concentration of B10AP within 
the NPs suspension was estimated by SDS-PAGE. A 
standard curve was built with a series of known B10AP 
suspensions (see ‘Materials & Methods’ within the 
Supplementary Information). Then, a series of three 
dilutions of AGuIX@B10AP@Cy5.5 stock solution 
was used to estimate the concentration of B10AP and 
thus estimate the ratio between (B10AP) and (Gd3+). 
This later was evaluated at 1 B10AP for 54 Gd3+, in 
other words, 1 B10AP for 5.4 NPs (Figure 1E & Table 1).
Affinities of functionalized NPs for amyloid 
fibrils
The formation of Aβ
(1–42)
, IAPP and V30M-TTR 
amyloid fibrils in vitro was assessed by Transmission 
Electronic Microscopy (Figure 2). NP–fibril interac-
tions were monitored by partition assays. Amyloid 
fibrils and NPs were incubated for 1.5 h; then, the NPs 
bound to amyloid fibrils were separated from the free 
ones by centrifugation, and the supernatants and the 
pellets were collected separately. At last, fluorescence 
spectra was recorded for the supernatants and the 
resuspended pellets. The fact that the sum of these two 
spectra was close to that of the suspension before cen-
trifugation indicated that no NPs were lost during the 
experiments (Figures 3A & 4A). The fluorescence inten-
sity of the pellets increased with the NP concentration 
at constant concentration of amyloid fibrils, showing 
that we were able to monitor the binding of the NPs 
(Figures 3B–D & 4B–D).
In the case of AGuIX@PEG@PIB (Figure 3B–D), 
the fluorescence changes at 420 nm allowed to esti-
mate K
D
 values of these NPs for the three types of 
amyloid fibrils. We were not able to use NP concentra-
tions high enough to reach a plateau for the binding 
(Figure 3B–D). However, the use of a simple Michaelis 
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Figure 1. Synthesis and characterization of AGuIX@PEG@PIB and AGuIX@B10AP@Cy5.5 a. Reaction schemes of AGuIX nanoparticles 
PEGylation followed by PIB grafting (upper scheme) and AGuIX cyanination followed by the grafting of B10AP (lower scheme). 
(B) Dynamic light scattering measurements of AGuIX (blue circle), AGuIX@PEG (black triangle) & AGuIX@PEG@PIB nanoparticles (red 
square). (C) Absorption quantification of PIB grafted on AGuIX@PEG (red markers) using standard curve of PEG@PIB (black circle) at 
λmax = 338 nm (A338). (D) Dynamic light scattering measurements of AGuIX@DOTAfree7% (blue circle), B10AP (black triangle) & AGuIX@
B10AP@Cy5.5 (red square). (E) SDS-PAGE quantification of B10AP in AGuIX@B10AP@Cy5.5 suspension using standard curve of B10AP. 
DMSO: Dimethyl sulfoxide; EDC: N-(3-Dimethylaminopropyl)-N0-ethylcarbodiimidehydrochloride; NHS: N-hydroxysuccinimide; 
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Figure 2. Transmission electron microscopy of amyloid fibrils. TEM pictures for Aβ(1–42) (A), IAPP (B) and V30M-
TTR (C) fibrils.Fibrils with mean apparent diameter of respectively 5, 10 and 12 nm for Aβ (1–42), IAPP and V30M-TTR 
are observed. Scale bar 100 nm. 
IAPP: Islet amyloid polypeptide.
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model, which assumed that the binding was noncoop-
erative, allowed a fair estimation of the K
D
: 15 ± 3 μM 
for Aβ
(1–42)
 fibrils, 21 ± 8 μM for IAPP fibrils and 57 ± 
27 μM for V30M-TTR fibrils. In the case of AGuIX@
B10AP@Cy5.5 (Figure 4B–D), the K
D
 values are: 46 ± 7 
nM for Aβ
(1–42)
, 21 ± 4 nM for IAPP and 264 ± 51 nM 
for V30M-TTR fibrils.
For all NPs tested, we checked that the binding was 
really due to B10AP and PIB by carrying out partition 
experiments with NPs but in the absence of fibrils. The 
results of these experiments showed that no signifi-
cant amount of NPs was pelleted due to aggregation 
(Supplementary Figure 2A). On the other hand, less 
than 5% of total fluorescence was measured in pellet 
for the partition experiments carried out with AGuIX@
Cy5.5 and amyloid fibrils (Supplementary Figure 2B). 
These results clearly indicated that there was no inter-
action between amyloid fibrils and NPs in the absence 
of the amyloid probes. All together, these results indi-
cated that both NPs specifically bound with the three 
types of amyloid fibrils tested, via the amyloid probe, 
and that B10AP NPs had a better affinity for amyloid 
fibrils compared with PIB NPs.
Tissue amyloid burden targeting
Then the capacity of each NP to detect amyloid bur-
den was tested on ex vivo tissue sections from mice 
model of each pathology: the brain of AD mice 
(Figure 5A–E, Figure 6A–E), the pancreas of T2DM 
mice (Figure 5F–G, Figure 6F–G) and the stomach of 
FAP mice (Figure 5H–I, Figure 6H–I). In AD mice brain, 
amyloid burdens are expected mainly within the hip-
pocampus and the cortex [42]. Spots exhibiting strong 
PIB fluorescence were detected within the hippocam-
pus on an AD brain slice imaged with AGuIX@PEG@
PIB (Figure 5C; blue color). They co-localized with 
ThS staining (Figure 5D; green color). A staining with 
phalloidin was also carried out to visualize the differ-
ent structures by labeling actin networks (Figure 5E). 
The merged image highlighted the co-localization of 
AGuIX@PEG@PIB and ThS staining, demonstrat-
ing that AGuIX@PEG@PIB selectively recognized 
the amyloid burden (Figure 5A). On pancreas sections 
from T2DM mice, PIB and ThS signal also co-local-
ized and were detected within selective and discrete 
areas at the level of Langherans islets, as expected for 
this type of model tissue [13] (Figure 5F). A similar co-
localization was also observed with stomach sections 
of FAP mice (Figure 5H) where V30M-TTR deposits 
have been described [43]. No fluorescence, and there-
fore no staining, was observed when similar imaging 
studies were carried out on control tissue sections, 
Table 1. Average hydrodynamic diameter of the AGuIX, AGuIX@PEG, AGuIX@PEG@PIB, AGuIX@
DOTAfree7% and AGuIX@B10AP@Cy5.5 nanoparticles and the grafting yield of targeting agent 
(Pittsburgh compound B or B10AP, grafted per nanoparticles).








2.9 ± 0.7 4.3 ± 1.0 6.5 ± 1.5 4.2 ± 0.7 13.9 ± 2.6
Quantification 
of grafting
– – 1 PIB:5 NPs – 1 B10AP:5.4 NPs*
PIB: Pittsburgh compound B.
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Figure 3.  Interaction in vitro between amyloid fibrils and AGuIX@PEG@PIB by partition experiments. (A) A total 
of 800 nM in PIB of AGuIX@PEG@PIB was added to 20 μM of Aβ (1–42) fibrils and the fluorescence of the suspension 
was measured (dotted line); then after 60 min of incubation, the suspension was centrifuged and the fluorescence 
of NPs bound to the amyloid fibrils (i.e., present in the pellet, solid line) and that of unbound NPs (i.e., present in 
the supernatant, dotted line) were measured (B, C & D). Determination of the KD using Michaelis model (1:1). The 
fluorescence intensity of NPs bound at approximately 420 nm is plotted as function of the total concentration of 
PIB functionalized on NPs, with Aβ (1–42) (B), IAPP (C) or V30M-TTR (D). The solid line represents the adjustment of 
the data to the Michaelis model (1:1) increasing concentration of PIB and fitted with. 
























































































KD = 15 ± 3 μM
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prepared from control mice who do not develop the 
diseases (Figure 5B, G & I). All together, these results 
clearly demonstrate the AGuIX@PEG@PIB selec-
tively labeled amyloid plaques on tissues from the mice 
model of the three pathologies investigated.
Similar experiments indicated that AGuIX@
B10AP@Cy5.5 also specifically stained amyloid depos-
its on the three types of tissues (Figure 6A, F, H). More-
over, the binding of AGuIX@B10AP@Cy5.5 can be 
detected through both the activity of AP (Figure 6C; 
red color) and the fluorescence of Cy5.5 (Figure 6D; 
yellow color). In brain sections of AD mice, these sig-
nals co-localized with ThS labeling (Figure 6E; green 
color) within the hippocampus. On the merged picture 
(Figure 6A), the three signals co-localized and resulted 
in intense yellow spots. Such co-localization of the three 
type of staining was also observed in pancreas tissue, 
and in particular in the Langherans islets of T2DM 
mice (Figure 6F). Note that a labeling of the cellular 
nucleus with Hoechst dye was also carried out on these 
later samples in order to easily identify Langherans islet 
(Figure 6F & G; blue color). Finally, with stomach tissue 
sections of FAP mice, a signal typically resulting from 
the co-localization of AGuIX@B10AP@Cy5.5 with 
ThS was also detected and assigned to amyloid depos-
its (Figure 6H). Finally, the specificity of the binding of 
AGuIX@B10AP@Cy5.5 to amyloid was confirmed by 
the absence of a fluorescence signal for similar experi-
10.2217/nnm-2017-0079 Nanomedicine (Lond.) (Epub ahead of print)
Figure 4. Interaction in vitro between amyloid fibrils and AGuIX@B10AP@cy5.5 by partition experiments. 
(A) A total of 11 nM in B10AP of AGuIX@B10AP@Cy5.5 was added to 40 μM of Aβ(1–42) fibrils and the 
fluorescence of the suspension was measured (dotted line); then after 60 min of incubation, the suspension was 
centrifuged and the fluorescence of NPs bound to the amyloid fibrils (i.e., present in the pellet, solid line) and that 
of unbound NPs (i.e., present in the supernatant, dotted line) were measured (B, C & D). Determination of the KD 
using Michaelis model (1:1). The fluorescence intensity of NPs bound at approximately 685 nm (Cy5.5 fluorescence) 
is plotted as function of the total concentration of B10AP functionalized on NPs, with Aβ (1–42) (B), IAPP (C) or 
V30M-TTR (D). The solid line represents the adjustment of the data to the Michaelis model (1:1) increasing 
concentration of B10AP and fitted with. 
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KD = 21 ± 4 nm
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ments carried out on control tissues which did not 
 contain amyloid deposition (Figure 6B, G & I).
Discussion
The aim of this work was to develop a specific, versatile 
and noninvasive tool detectable by medical imaging 
able to specifically target amyloid deposits for a more 
sensitive and early diagnostic of amyloidosis.
One of the important features of functionalization 
of NPs is the control of the synthesis in terms of chemi-
cal reaction, quality of grafting and size of the final 
product. The grafting of PIB to AGuIX NPs increases 
their hydrodynamic diameter (Table 1). However, their 
size remains homogenous (Figure 1A) and their relaxo-
metric characterization shows good relaxivity at 12.9 
mM-1.s-1 allowing MRI detection. Therefore, the Gd3+ 
relaxation properties of the NPs are not altered by the 
grafting.
The affinity of AGuIX@PEG@PIB for amyloid 
fibrils is approximately 10 μM, close to the value that 
was previously reported for PIB alone [23]. The addi-
tion of the PEG linker between PIB and the NP allows 
PIB to be sufficiently accessible to interact with its tar-
get. One can note here, that the dissociation constants, 
that have been measured for PIB in this work, are sev-
eral orders of magnitude higher than those reported 
10.2217/nnm-2017-0079www.futuremedicine.com
Figure 5. Amyloid deposit targeting with AGuIX@PEG@PIB in pathological tissue. Specific targeting of amyloid 
plaques with AGuIX@PEG@PIB nanoparticles on brain sections of APPswe/PSE1d9 mice (A, C–E), on pancreas 
sections of S/FVB/N-Tg/(ins2-hIAPP) mice (F) or stomach sections of transgenic V30M-TTR mice (H) and on 
respective negative control tissues: C57/Bl6 mice (B), S/FVB/NJ mice (G) and KO-TTR mice (I). Nanoparticles 
targeting were detected via the PIB fluorescent signal (C, blue color). Amyloid plaques were visualized using 
Thioflavin-S staining (D, green color). The co-localization between nanoparticles and amyloid plaques were 
obtained by merging PIB and ThS fluorescent staining (A, F & H, white arrows). TRITC-conjugate of phalloidin was 
used to label cellular actin filament (E, red color). 
AD: Alzheimer’s disease; CTRL: Control; FAP: Familial amyloidotic polyneuropathy; IAPP: Islet amyloid 









Gd-NPs functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting    Research Article
in the literature [11,25–26]. The reasons for this appar-
ent discrepancy are unknown, but the conditions and 
the methods used in our experiments are drastically 
different. As PIB has kept both its optical properties 
10.2217/nnm-2017-0079 Nanomedicine (Lond.) (Epub ahead of print)
Figure 6. Amyloid deposit targeting with AGuIX@PEG@Cy5.5 in pathological tissue. Specific targeting of 
amyloid plaques with AGuIX@B10AP@Cy5.5 nanoparticles on brain slices of APPswe/PSE1d9 mice (A, C–E), on 
pancreas sections of S/FVB/N-Tg/(ins2-hIAPP) mice (F) or stomach section of transgenic V30M-TTR mice (H) and 
on respective sections of negative control tissues: C57/Bl6 mice (B), S/FVB/NJ mice (G) and KO-TTR mice (I). 
Nanoparticles targeting were detected due to both red permanent reaction with alkaline phosphatase (C, red 
color) and Cy5.5 fluorescent signal (D, yellow color). Amyloid plaques were visualized using Thioflavin-S dye 
staining (E, green color). The co-localization between nanoparticles and amyloid plaques were obtained by 
merging red permanent, Cy5.5 and Thio-S fluorescent staining (A, F, H, white arrows). Cellular nucleus of the 
tissue were stained with Hoechst dye (F, G, blue color). 
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and its ability to recognize amyloid aggregates, the 
 multimodality of the NPs has been confirmed.
A further milestone for the development of new 
multimodal NPs has been reached with the success-
ful grafting of B10AP. This was a challenge because 
of constraints implied by the use of a multidomain 
protein. The affinity of AGuIX@B10AP@Cy5.5 for 
both Aβ and IAPP fibrils is approximately 10 nM 
(Figure 4B–C), and is comparable both to that measured 
with B10AP alone (8.3 nM for Aβ
(1–42)
, not shown) 
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and to that reported in the literature [32]. These results 
clearly demonstrate that B10 remains functional upon 
grafting to the NPs. Therefore, AGuIX NP may also 
constitute an interesting platform for high molecular 
weight molecules.
The ability of the functionalized NPs to stain 
amyloid fibrils on ex vivo tissues, was investigated by 
immunohistochemistry experiments performed on 
pathological tissues from mice model of each disor-
der. AGuIX@PEG@PIB or AGuIX@B10AP@Cy5.5 
fluorescence is observed in all tested pathological tis-
sues on distinct amyloid spots (Figures 5 & 6). In such 
experiments, the co-localization of Cy5.5 fluorescence 
and AP activity signal in the same restricted zones was 
a further proof of the integrity of AGuIX@B10AP@
Cy5.5. In addition, the fact that both NPs co-localized 
with Thioflavin-S staining, confirms their specific 
 targeting of amyloid burden.
The determination of the equilibrium dissocia-
tion constant of these NPs is important for estimat-
ing their potential as diagnosis tools. The affinity for 
amyloid fibrils of AGuIX@PEG@PIB is in the 10 μM 
range and that of AGuIX@B10AP@Cy5.5 in the 10 
nanomolar range. Such values are compatible with the 
use of such NP for in in vivo studies (Figures 3 & 4). 
The dissociation constant of AGuIX@B10AP@Cy5.5 
for V30M-TTR fibrils is significantly larger than for 
the other two types of fibrils. The reason for this lower 
affinity is unknown. However, it has been reported 
that B10 does not recognize all amyloid fibrils with 
the same efficiency [32]; this compromises its use for 
diagnostic. This work, however, clearly demonstrates 
that large multidomain proteins can be efficiently 
linked to AGuIX; this proof of concept opens the pos-
sibility to functionalize these NPs with nanobodies 
recognizing selective epitopes of the AD at the surface 
of extracellular amyloid plaque or intracellular tar-
gets [44]. Moreover, small peptides with high affinity 
(K
D
 in 10 nanomolar range [45,46]) for a generic epitope 
at the surface of Aβ amyloid fibrils have been recently 
described and could also constitute valuable probes 
to be grafted on AGuIX. Nevertheless, these peptides 
present important drawbacks since they induce cell 
toxicity [45] or stabilize protofibrils [46]. Some other 
peptides specifically targeting Aβ-peptide fibrils with 
no toxic effects have been described but their affini-
ties are too low for in vivo imaging (100 micromolar 
range) [23].
Conclusion
In this work, we have shown that AGuIX can be suc-
cessfully functionalized with a small molecule and a 
large protein to specifically target amyloid fibrils. Thus, 
the NPs tested in this work provide complementary 
tools that could be useful for in vivo diagnostic: strong 
affinity of AGuIX@B10AP@Cy5.5 will be helpful for 
early amyloid deposits detection, when the smaller size 
of AGuIX@PEG@PIB should diffuse more quickly, 
particularly interesting notably for systemic amyloi-
dosis (V30M-TTR). In the case of AD diagnostic, we 
must take into account that such NPs have to reach 
their target inside the brain, implicating the crossing 
of the hermetic blood–brain barrier. However, the flex-
ibility of AGuIX NPs may allow chemical modifica-
tions for diffusion through this barrier or addition of 
molecules to improve active transport through specific 
receptor of the blood–brain barrier.
In any case, such functionalized NPs are very prom-
ising to target several types of amyloid deposits in vivo, 
because of their very low levels of toxicity; their rapid 
clearance [47]; and the divert and complementarity of 
imaging techniques with great sensitivity and spatial 
resolution that can be used.
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•	 To achieve the diagnostic of amyloidosis, multimodal imaging nanoparticles were functionalized with either 
the Pittsburgh compound B or a nanobody.
•	 Efficient active targeting was tested by spectroscopic and biophysics techniques on Aβ (1–42), IAPP and 
Val30MetTTR fibrils.
•	 Both nanoparticles efficiently interacted with the three types of amyloid fibrils, with KD values in 10 
micromolar range for AGuIX@PIB and 10 nmolar range for AGuIX@Cya5.5@B10AP.
•	 Both functionalized nanoparticles are able to interact specifically with amyloid deposits localized in 
pathological tissue.
•	 These functionalized nanoparticles represent promising flexible devices for multimodal imaging in early 
diagnostic of amyloid plaques, in other words, Alzheimer’s disease, Type 2 diabetes mellitus and the familial 
amyloidotic polyneuropathy.
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